This company has been acquired
Amryt Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Amryt Pharma has a total shareholder equity of $324.3M and total debt of $208.6M, which brings its debt-to-equity ratio to 64.3%. Its total assets and total liabilities are $736.9M and $412.6M respectively.
Key information
64.3%
Debt to equity ratio
US$208.60m
Debt
| Interest coverage ratio | n/a |
| Cash | US$83.25m |
| Equity | US$324.28m |
| Total liabilities | US$412.60m |
| Total assets | US$736.88m |
Recent financial health updates
Recent updates
Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU
Oct 18Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval
Sep 16Amryt gets British marketing approval & orphan drug designation for rare skin disease gel
Sep 08Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition
Jul 14Amryt's Filsuvez gets approval in EU to treat rare skin disorder
Jun 23Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions
Dec 09Chiasma surges on merger agreement with Amryt
May 05Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept
Feb 04Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder
Dec 23Amryt Group's Lojuxta receives marketing approval in Brazil
Dec 09Financial Position Analysis
Short Term Liabilities: AMYT's short term assets ($224.4M) exceed its short term liabilities ($143.1M).
Long Term Liabilities: AMYT's short term assets ($224.4M) do not cover its long term liabilities ($269.5M).
Debt to Equity History and Analysis
Debt Level: AMYT's net debt to equity ratio (38.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if AMYT's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AMYT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AMYT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 45.1% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/14 01:39 |
| End of Day Share Price | 2023/04/11 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amryt Pharma plc is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michelle Gilson | Canaccord Genuity |
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Andrew Young | Davy |